In addition, TNFRSF4 can potentially be used as a molecular target to reduce the function of Treg and improve the anti-tumor immunity against NSCLC, which help us better understand the mechanism of cell synergy in the clinical response to neoadjuvant immunotherapy. The gene discussed is TNFRSF4; the disease is neoplasm.